Company profile

TolerogenixX

VZP0468 | Baden-Württemberg

TolerogenixX has an innovative cell technology that can be used to suppress unwanted immune responses in the body. This novel cell therapy will revolutionize the treatment of transplant recipients and numerous autoimmune diseases. The unique feature of the TolerogenixX method is the simple modification of white blood cells by use of the TolerogenixX therapy kit. Once infused, these modified cells suppress unwanted immune responses in the patient´s body. The first patients have already been successfully treated in a phase-I clinical study in kidney transplantation. Due to the promising results from the phase I study, there are already preparations for the TOL-2 phase II study.

Industry

  • Life Science

Registered office

Im Neuenheimer Feld 162
69120 Heidelberg
Deutschland

Spots

VZP number

VZP0468

Founding year

2018

Employees

8

Legal form

GmbH

Products

ATMP, Zelltherapie, Therapie-Kit

Business model

Production

Company stage

Start-up Stage (Unternehmensgründung, PoC, Prototypenentwicklung und Markteinführung)

Funding stage

Seed Financing

Customer focus

B2B (Business to Business)

Geografic focus

weltweit